BAYRY (BAYRY) Stock Price & Analysis
BAYRY (BAYRY) rose 0.30% to USD 10.18 as of June 9, 2026 at 23:53 UTC, according to Nexqual real-time market data.
BAYRY last closed at USD 10.15; the session ranged USD 10.14–10.3 on volume of 37,129 shares. Market capitalization is $40.00B, with a 52-week range of USD 7.19–14.85 (OQX). Source: Nexqual, June 9, 2026 at 23:53 UTC.
Key Statistics (as of June 9, 2026 at 23:53 UTC)
| Price | USD 10.18 |
|---|---|
| Change | ▲ 0.30% (up) |
| Previous Close | USD 10.15 |
| Open | USD 10.21 |
| Day Range | USD 10.14 – 10.3 |
| 52-Week Range | USD 7.19 – 14.85 |
| Volume | 37,129 shares |
| Market Cap | $40.00B |
| Exchange | OQX |
Technical Analysis (BAYRY)
Nexqual's technical model rates BAYRY "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:53 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 36.27 (neutral) |
| vs SMA50 | Below (USD 11.11) |
| MACD | -0.28 (negative) |
Analyst Ratings (BAYRY)
Wall Street analysts rate BAYRY "Buy" based on 4 analysts, with a mean price target of USD 14.2 (range USD 11.7–15.3), per Nexqual as of June 9, 2026 at 23:53 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 14.2 |
| High Target | USD 15.3 |
| Low Target | USD 11.7 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (BAYRY)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.26 |
| Revenue Estimate | $10.75B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.79 vs est 0.62 ▲ beat |
| 2025-12-31 | USD 0.18 vs est 0.16 ▲ beat |
| 2025-09-30 | USD 0.17 vs est 0.13 ▲ beat |
| 2025-06-30 | USD 0.36 vs est 0.25 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:53 UTC.
Financials & Fundamentals (BAYRY)
| Total Revenue | $45.24B |
|---|---|
| Revenue Growth (YoY) | -2.40% |
| Gross Margin | +59.92% |
| Operating Margin | +26.32% |
| Profit Margin | -4.76% |
| ROE | -6.93% |
| Debt / Equity | 134.27 |
| Current Ratio | 1.06 |
| Total Cash | $6.66B |
| Total Debt | $38.89B |
| Free Cash Flow | $7.31B |
Source: Nexqual, June 9, 2026 at 23:53 UTC.
Financial Health Score (BAYRY)
Nexqual rates BAYRY's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:53 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 60%, operating 26% |
| Balance Sheet | Mixed — $6.66B cash vs $38.9B debt |
| Cash Flow | Strong — FCF $7.31B, 16% margin |
| Efficiency | Critical — ROE -7%, ROA 3.6% |
Ownership (BAYRY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.44% |
| Shares Outstanding | 3.93B |
| Float | 3.93B |
Source: Nexqual, June 9, 2026 at 23:53 UTC.
Leadership (BAYRY)
BAYRY is led by William N. Anderson (age 59), Chairman of the Management Board & CEO, per Nexqual as of June 9, 2026 at 23:53 UTC.
| Chairman of the Management Board & CEO | William N. Anderson (age 59) |
|---|---|
| Chief Talent Officer, Labor Director & Member of Management Board | Heike Prinz (age 61) |
| CFO & Member of Management Board | Judith Hartmann (age 56) |
| Member of Management Board, Head of the Crop Science Division & President of Crop Science Division | Rodrigo Santos (age 52) |
| Member of Management Board & President of Consumer Health Division | Julio Triana (age 60) |
Major Backers & Investors (BAYRY)
Notable institutional backers of BAYRY include 2023 ETF Series Trust-Eagle Capital Select Equity ETF, Kahn Brothers Group Inc., Dodge & Cox Funds-Dodge & Cox Balanced Fund, according to Nexqual as of June 9, 2026 at 23:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| 2023 ETF Series Trust-Eagle Capital Select Equity ETF | 0.19% |
| Kahn Brothers Group Inc. | 0.17% |
| Dodge & Cox Funds-Dodge & Cox Balanced Fund | 0.16% |
Source: Nexqual, June 9, 2026 at 23:53 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BASFY | BASF SE | USD 14.06 | ▼ 4.16% |
| RHHBY | Roche Holding Ltd | USD 50.01 | ▼ 2.86% |
| SIEGY | Siemens AG | USD 152.95 | ▼ 0.03% |
| SNY | Sanofi | USD 44.73 | ▼ 0.64% |
| NVS | Novartis AG | USD 149.12 | ▼ 0.03% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:53 UTC. This page is informational and not investment advice.